Tumor markers for cancer detection. II

Area of Science:

• Oncology
• Biochemistry
• Clinical Diagnostics

Background:

• Prospective studies are crucial for evaluating diagnostic tools in real-world settings.
• Tumor markers have shown potential in cancer screening, but their utility in asymptomatic populations requires further investigation.
• Early cancer detection significantly improves patient outcomes and treatment efficacy.

Purpose of the Study:

• To assess the effectiveness of tumor marker determinations in identifying individuals at risk for cancer within a seemingly healthy population.
• To evaluate the diagnostic value of various tumor markers, including CEA, AFP, beta-HCG, beta 2-M, ferritin, beta 1-SP, TPA, CA 12-5, and CA 19-9.
• To compare CEA determination methods using monoclonal versus polyclonal antibodies.

Main Methods:

• A prospective study involving 2,000 supposedly healthy individuals with a 1- to 6-year observation period (mean 3.5 years).
• Routine tumor marker determinations using radioimmunoassay (RIA) for CEA, AFP, beta-HCG, beta 2-M, ferritin, and beta 1-SP.
• Preliminary data collection for TPA, CA 12-5, and CA 19-9.
• Comparative analysis of CEA assays employing monoclonal and polyclonal antibodies.

Main Results:

• The "at-risk" group (n=481) with at least one abnormal marker value had a cancer detection rate of 29 per 1,000.
• The "normal" group (n=1,519) had a cancer detection rate of 3.2 per 1,000, a statistically significant difference.
• A total of 27 malignancies were detected, with tumor marker associations showing promise for risk stratification.

Conclusions:

• Tumor marker determinations are valuable for identifying individuals at increased risk of developing cancer within a general population.
• Combining general tumor markers (CEA, TPA, CA 19-9) with site-specific markers (PAP, CA 12-5) enhances their role in cancer risk assessment.
• Polyclonal antibodies are recommended for CEA determination due to superior performance.